Stifel Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $28
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Stifel analyst Stephen Willey initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $28.
Stifel analyst Stephen Willey initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $28.